Healthcare
Kissei Pharmaceutical Co., Ltd.(KSPHF)
Live Price
Offline$25.77
+0.00% today
1Y Change
-5.01%
Window
Jun 25, 2025 → Jun 18, 2026
- Market Cap
- $179.08B
- Revenue Growth
- +16.9%
- EPS Growth
- +11.2%
- Dividend Yield
- 3.7%
Coverage: 252 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kissei Pharmaceutical Co., Ltd. (KSPHF) is a Healthcare stock with a market cap of $179.08B and listed on OTC. The stock last traded around $25.77 and down 5.0% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +16.9%, EPS growth of +11.2%, a dividend yield of 3.7%. What stands out right now is revenue +16.9%, EPS +11.2%, free cash flow +142.5% with operating margin -2.3% and ROIC -0.7%. The dividend matters to the case here, with a current yield around 3.7%. Valuation is more restrained than many high-expectation growth names at P/E 12.7 and price/sales 1.9. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines KSPHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.9% vs +7.6% peer median
Operating Margin
Below sector median
-2.3% vs +19.4% peer median
P/E
Below sector median
12.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +16.9% and EPS at +11.2%, with operating margin around -2.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.7%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
KSPHF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KSPHF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KSPHF Max Drawdown
-19.22%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KSPHF and SPY.
Company Overview
Kissei Pharmaceutical Co., Ltd.
Other OTC
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. Its products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was incorporated in 1946 and is headquartered in Matsumoto, Japan.
- Leadership
- Mutsuo Kanzawa
- IPO Date
- Mar 17, 2017
- Employees
- 1.8k
- Street Address
- 19-48, Yoshino
- Mailing
- Matsumoto, 399-8710
- Region
- Matsumoto, JP
- Reporting Currency
- USD
- Investor Line
- 81 263 25 9081
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 12.7
- EV/EBITDA
- 7.3
- Price/Sales
- 1.9
- Price/Book
- 0.8
Growth
- Revenue
- +16.9%
- EPS
- +11.2%
- Free Cash Flow
- +142.5%
Profitability
- Gross Margin
- 48.2%
- Operating Margin
- -2.3%
- Net Margin
- 14.8%
- ROE
- 6.7%
- ROIC
- -0.7%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 4.50
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.